DTaP-Hib-MCV4 vaccine

DTaP-Hib-MCV4 vaccine (also referred to as DTcP-Hib-MCV4 Combined Vaccine) is an investigational pentavalent combination vaccine developed by CanSino Biologics. It is designed to simultaneously protect healthy children aged 2 months to 6 years against five major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), Haemophilus influenzae type b (Hib) infections, and meningococcal meningitis caused by serogroups A, C, Y, and W135. The vaccine is formulated by combining acellular pertussis antigens (components), diphtheria and tetanus toxoids, a Hib polysaccharide conjugate, and a quadrivalent meningococcal conjugate (MCV4) based on CanSinoBIO's commercialized Menhycia® vaccine. By combining these components, the vaccine aims to reduce the number of required injections, improving vaccination compliance and efficiency. It is currently in Phase I clinical development in China.

Other names

DTcP-Hib-MCV4 Combined VaccineDTcP-Hib-MCV-4 Combined VaccineDTcP-Hib-MCV 4 Combined VaccineDTcP-Hib-MCV4 vaccineDTcP-Hib-MCV-4 vaccineDTcP-Hib-MCV 4 vaccineabsorbed diphtheria, tetanus and acellular pertussis (components), Haemophilus influenzae type b (conjugate) and group ACYW135 meningococcal (conjugate) combined vaccine吸附无细胞百（组分）白破b型流感嗜血杆菌（结合）-ACYW135群脑膜炎球菌（结合）联合疫苗